课题基金 / 基金详情

Task 2/F04: Pharmacokinetic and Safety/Tox Testing for Therapeutics

Task 2/F04: Pharmacokinetic and Safety/Tox Testing for Therapeutics
任务 2/F04:治疗药物的药代动力学和安全性/毒性测试
批准号:
8338703
负责人:
MARA KUMMINS
金额:
$19.29万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-30 至 2012-08-30

项目摘要

项目成果

MARA KUMMINS的其他基金

相似基金

相关文献

中文摘要
翻译
新出现疾病和生物防御的体外和动物模型合同提供小动物和非人类灵长类动物模型的开发和标准化,并可能包括疫苗和/或疗法的有效性测试,包括支持产品许可的GLP研究。在小动物身上有效的疫苗和疗法可能会在非人类灵长类动物模型中进一步测试。该合同还提供疫苗的安全性和免疫原性测试,包括在小动物和非人类灵长类动物中的体液和细胞免疫,在适当的情况下,根据GLP。此外,它还可以根据GLP在适当的情况下在小动物和非人类灵长类动物身上进行治疗安全性和药理学的测试。
英文摘要
The In Vitro and Animal Models for Emerging Diseases and Biodefense contract provides the development and standardization of small animal and non-human primate models, and may include efficacy testing of vaccines and/or therapeutics, including GLP studies to support product licensure. Vaccines and therapeutics which are efficacious in small animals may be further tested in non-human primate models. This contract also provides testing of vaccines for safety and immunogenicity, to include humoral and cellular immunity, in small animals as well as non-human primates, under GLP where appropriate. In addition, it can perform testing of therapeutics for safety and pharmacology, in small animals as well as non-human primates, under GLP where appropriate.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ENTITLED SUPPORT SERVICES FOR THE NATIONAL PROGRAM TO REDUCE CARDIOVASCULAR RISK
  • 批准号:
    8356259
  • 项目类别:
  • 资助金额:
    $274.97万
  • 财政年份:
    2011
  • 负责人:
    MARA KUMMINS
  • 依托单位:
MANUFACTURE OF 3KG OF DMAU UNDER CGMP GUIDANCE
  • 批准号:
    8288464
  • 项目类别:
  • 资助金额:
    $106.68万
  • 财政年份:
    2011
  • 负责人:
    MARA KUMMINS
  • 依托单位:
NIH AIDS Research and Reference Reagent Program
  • 批准号:
    8338751
  • 项目类别:
  • 资助金额:
    $411.26万
  • 财政年份:
    2005
  • 负责人:
    MARA KUMMINS
  • 依托单位:
PEDIATRIC OFF-PATENT DRUGS STUDY (PODS)
  • 批准号:
    8329190
  • 项目类别:
  • 资助金额:
    $5.7万
  • 财政年份:
    2004
  • 负责人:
    MARA KUMMINS
  • 依托单位:
海外基金